| Identification | Back Directory | [Name]
RTC13 | [CAS]
1359825-94-7 | [Synonyms]
RTC13
RTC13 >=98% (HPLC)
Read-through compound 13
4(5H)-Thiazolone, 2-amino-5-[[5-(2-nitrophenyl)-2-furanyl]methylene]-, (5Z)- | [Molecular Formula]
C14H9N3O4S | [MDL Number]
MFCD28398016 | [MOL File]
1359825-94-7.mol | [Molecular Weight]
315.3 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: 20mg/mL, clear | [form ]
Solid | [color ]
Orange to red | [InChI]
1S/C14H9N3O4S/c15-14-16-13(18)12(22-14)7-8-5-6-11(21-8)9-3-1-2-4-10(9)17(19)20/h1-7H,(H2,15,16,18)/b12-7+ | [InChIKey]
CZZAPCPWFCGOCC-KPKJPENVSA-N | [SMILES]
O=C1NC(S/C1=C\C2=CC=C(C3=C([N+]([O-])=O)C=CC=C3)O2)=N |
| Hazard Information | Back Directory | [Description]
RTC13 is a premature termination codon (PTC) readthrough inducer that acts by restoring dystrophin expression and improving muscle function in the mdx mouse model for Duchenne muscular dystrophy. | [Uses]
RTC13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy (DMD)[1]. | [in vivo]
| Animal Model: | Wild-type (C57BL/10) mice at 10 to 12 weeks of age[1].
| | Dosage: | 10 (n = 5), 30 (n = 5), 60 (n = 5) or 300 mg/kg (n = 5). | | Administration: | Intraperitoneal Administration. | | Result: | No changes were observed in liver and kidney weights at the time of necropsies, and Hematoxylin and Eosin (H&E) staining revealed the absence of histopathological changes. |
| [References]
[1] Refik Kayali, et al. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet. 2012 Sep 15;21(18):4007-20. DOI:10.1093/hmg/dds223 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|